BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...
BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...
BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
tumor distribution of TMZ in V+ SC and V+ IC rat glioma models after another<br />
anti-angiogenic agent 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl] indolin-2-one (SU5416)<br />
administration [147]. SU5416 (25 mg/kg) or vehicle control was administrated<br />
intraperitoneally (IP) daily for a total of nine doses. Two days after the last dose of<br />
SU5416 or vehicle control, TMZ was administration as a steady-state infusion regimen to<br />
achieve plasma concentrations of 20 μg/ml. In V+ SC tumors, a 24% reduction in<br />
steady-state plasma TMZ concentration as well as a 21% reduction in tumor-to-plasma<br />
concentration ratio was documented compared with controls. This reduction was also<br />
accompanied by a 20 to 35% reduction in MVD. In contrast with TNP-470 study, In a V+<br />
IC tumor xenograft model, steady-state plasma TMZ concentration and tumor-to-plasma<br />
ratio were significantly increased by 2-fold after SU4516 treatment compared to controls.<br />
The authors discussed that the differential effects of SU4516 in tumor distribution of<br />
TMZ in V+ SC and V+ IC tumor models may be attributed to the microdialysis sampling<br />
site, peripheral versus central, and the dimethyl sulfoxide administration vehicle.<br />
In contrast to the reduction of cytotoxic drug penetration and concentration in<br />
tumor tissue after antiangiogenesis therapy, there were publications showed that<br />
antiangiogenic agents can improve the drug delivery to tumor site in addition to the<br />
observation in V+ IC rate model discussed in above paragraph. Gallo and colleagues<br />
published two papers [51, 148] that demonstrated that a lower dose of sunitinib<br />
significantly increased TMZ tumor distribution in two mice glioma xenografts when<br />
compared to a higher dose or control group. In mice bearing SF188V+ human glioma<br />
xenografts, vehicle, sunitinib (10 mg/kg) or sunitinib (40 mg/kg) was given everyday<br />
orally up to 14 days [51]. One day after the last dose of vehicle or sunitinib, TMZ was<br />
administrated as a single oral dose at 20 mg/kg. Both sunitinib dosage 10 mg/kg and 40<br />
mg/kg increased temozolomide tumor distribution by using tumor-to-plasma AUC ratio<br />
compared to control group. However, only 10 mg/kg group reached statistical<br />
significance (p